Table 1.
Association between vitronectin expression and clinicopathological characteristics in TCGA gastric cancer patients.
| VN expression | |||
| Variables | Low (N = 328) | High (N = 19) | P value |
| Gender (%) | .084 | ||
| Male | 208 (63.4) | 16 (84.2) | |
| Female | 120 (36.6) | 3 (15.8) | |
| Age (mean ± SD, yrs) | 65.4 ± 10.4 | 62.4 ± 10.0 | .212 |
| Grade type (%) | .679 | ||
| G1 | 9 (20.0) | 0 (0.0) | |
| G2 | 114 (35.6) | 8 (42.1) | |
| G3 | 197 (33.3) | 10 (52.6) | |
| Unknown | 8 (2.4) | 1 (5.3) | |
| Pathological T stage (%) | .653 | ||
| T1 | 15 (4.6) | 0 (0.0) | |
| T2 | 67 (20.4) | 5 (26.3) | |
| T3 | 154 (47.0) | 7 (36.8) | |
| T4 | 88 (26.8) | 7 (36.8) | |
| Unknown | 4 (1.2) | 0 (0.0) | |
| Pathological N stage (%) | .049 | ||
| N0 | 101 (30.8) | 4 (21.1) | |
| N1 | 91 (27.7) | 3 (15.8) | |
| N2 | 69 (21.0) | 3 (15.8) | |
| N3 | 61 (18.6) | 9 (47.7) | |
| Unknown | 6 (1.8) | 0 (0.0) | |
| Pathological M stage (%) | <.001 | ||
| M0 | 300 (91.5) | 12 (63.2) | |
| M1 | 28 (8.5) | 7 (36.8) | |
| TNM stage (%) | .002 | ||
| I | 43 (13.1) | 2 (10.5) | |
| II | 106 (32.3) | 3 (15.8) | |
| III | 138 (42.1) | 7 (36.8) | |
| IV | 28 (8.5) | 7 (36.8) | |
| Unknown | 13 (4.0) | 0 (0.0) | |